Home » Topics » BioWorld Science

BioWorld Science
RSS

Discovery of EGFR inhibitors against L858R/T790M/C797S resistance mutations

June 2, 2022

SMARD1 murine model shows respiratory defects and muscular atrophy

June 2, 2022

Novel NPR-C activator for the treatment of cardiovascular disease

June 2, 2022

ATAD3A is a therapeutic target in Alzheimer's disease

June 2, 2022

Scorpion Therapeutics patents EGFR and/or HER2 inhibitors

June 2, 2022

New Ret inhibitors discovered at Lilly

June 2, 2022

Mirati Therapeutics, Array BioPharma present KRAS Gly12Asp inhibitors

June 2, 2022

Kronos Bio synthesizes new PROTAC CDK9 degradation inducers

June 2, 2022

New MAP4K 1inhibitors identified at Merck & Co.

June 2, 2022

Researchers present novel Hermansky-Pudlak syndrome murine model

June 2, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...